† 5′-Adenosine monophosphate-activated protein kinase (AMPK) is a master regulator of energy homeostasis in eukaryotes. Despite three decades of investigation, the biological roles of AMPK and its potential as a drug target remain incompletely understood, largely because of a lack of optimized pharmacological tools. We developed MK-8722, a potent, direct, allosteric activator of all 12 mammalian AMPK complexes. In rodents and rhesus monkeys, MK-8722-mediated AMPK activation in skeletal muscle induced robust, durable, insulin-independent glucose uptake and glycogen synthesis, with resultant improvements in glycemia and no evidence of hypoglycemia. These effects translated across species, including diabetic rhesus monkeys, but manifested with concomitant cardiac hypertrophy and increased cardiac glycogen without apparent functional sequelae.
T he 5′-adenosine monophosphate-activated protein kinase (AMPK) pathway is the primary mechanism for detecting and responding to changes in cellular energy levels in eukaryotes (1) . AMPK is a Ser/Thr protein kinase consisting of one a-catalytic subunit (two isoforms), one b-"scaffold" subunit (two isoforms), and one g-regulatory subunit (three isoforms) (2) . Excluding splice variants, higher mammals therefore possess 12 distinct AMPK complexes. Physiological activation of AMPK function is mediated by a-subunit Thr 172 phosphorylation (yielding pAMPK) as well as by allosteric activation and is regulated by changes in intracellular "adenylate charge" and calcium levels (3) . AMPK activation has a broad impact on carbohydrate and lipid metabolism via pAMPKmediated phosphorylation of downstream target proteins (1) (2) (3) . For example, pAMPK induces insulin-independent skeletal muscle glucose uptake by increasing localization of Glut4 to the plasma membrane (4) and further stimulates intracellular glucose utilization by increasing glycogen synthesis (5) and likely glycolysis (6) . In part because of these effects, AMPK activation represents a potential target for the treatment of type 2 diabetes mellitus (T2DM) (7) as well as other metabolic diseases and cancer (8) .
Conversely, numerous dominant missense mutations have been identified in the nucleotidebinding region of the human AMPK g2 subunit (PRKAG2 mutations) (8, 9) . These disinhibition/ gain-of-function mutations result in hypertrophic cardiomyopathy and electrocardiogram (ECG) abnormalities as well as increased cardiac glycogen. A key question is which, if any, of these pathologies would be replicated by pharmacological activation of AMPK in mature animals.
Despite widespread interest, few direct systemic pan-AMPK activators have been described to date (10, 11) . The majority of reported activators are indirect and work by elevating cellular AMP and ADP (adenosine mono-and diphosphate) levels (12) . By contrast, direct AMPK activators fall into two main classes: (i) nucleoside analogs of adenosine, such as the widely used 5-aminoimidazole-4-carboxamide ribofuranoside (AICAR), which is 5′-phosphorylated in cells to the active ribonucleotide (ZMP), and (ii) non-nucleoside activators, the most widely studied of which is A-769662, which is b1 complex-selective. Here, we report the development and biological effects of MK-8722 (Fig. 1A) , a potent pan-activator of all 12 mammalian AMPK isoforms.
MK-8722 activates pAMPK complexes with increased potency and magnitude versus AMP (see e.g., Fig. 1B) , with half-maximal effective concentration (EC 50 ) values of~1 to 60 nM and increased activation by factors of~4 to 24 (table  S1) . Although MK-8722 exhibits higher affinity for b1-containing (~1 to 6 nM) versus b2-containing (~15 to 63 nM) pAMPK complexes, it is the most potent activator of b2 complexes reported to date (11) . pAMPK activation by maximal AMP plus MK-8722 is synergistic (Fig. 1C) , demonstrating that the agents act at distinct sites. This is consistent with x-ray crystallography data obtained for compound 991 (a precedent structural analog of MK-8722) bound to pAMPK (13) . Homology modeling strongly suggests that MK-8722 and 991 bind pAMPK in a similar manner ( fig. S1 ).
MK-8722 has high cell permeability [apparent permeability coefficient P app = 17 × 10 −6 cm/s in Lilly Laboratories porcine kidney (LLC-PK1) cells]. Activation of intracellular AMPK was assessed on the basis of ability to induce AMPK-mediated, sitespecific phosphorylation of acetyl-coenzyme A carboxylase (ACC; both isoforms 1 and 2) to generate pACC (14) and the degree of AMPK phosphorylation. These effects were routinely quantitated using a Meso Scale Discovery (MSD) assay for pACC and an enzyme-linked immunosorbent assay (ELISA) for pAMPK (all data reported unless otherwise indicated). Similar results were generated using Western blot analysis (see e.g., fig. S2 ). MK-8722 induced pACC formation in all cells tested, with a factor of~1000 potency enhancement and increased activation versus AICAR ( Fig. 1D and  fig. S3 ). Notably, pACC formation was nearly maximal at MK-8722 concentrations that did not measurably increase pAMPK; this result suggests that MK-8722 activation may not require pAMPK in cells, similar to findings for A-769662 (15) . The effects of MK-8722 (0.5 mM), as well as those of the well-known activators ionomycin (1 mM; a calcium ionophore) and AICAR (500 mM), on pACC were largely blocked by pretreatment of cells with the nonspecific AMPK inhibitor Compound C (16) (40 mM) (Fig. 1E ). As expected, MK-8722 treatment of primary mouse hepatocytes, HepG2 cells, or primary human myocytes resulted in the phosphorylation of a number of additional known targets of pAMPK (figs. S4 and S5). In a broad array of pharmacologically relevant targets (120 assays, including various enzymes, receptors, ion channels, and transporters), the most potent off-target activity observed for MK-8722 was against the serotonin 5-HT 2A receptor (inhibitor dissociation constant K I = 2.8 mM). MK-8722 treatment did not lead to decreases in cellular ATP in vitro ( fig. S6 ), similar to our secondgeneration activator 991 (17) . Furthermore, no overt toxicity has been observed in cell-based studies or upon acute or chronic dosing in vivo. These results are consistent with the selective action of MK-8722 as a direct AMPK activator. MK-8722 has biochemical (table S1) and pharmacokinetic (table S2) properties that reproducibly enable systemic and sustained AMPK activation across species after once-daily oral dosing. The unbound fraction of MK-8722 in mammalian plasma is~0.1%.
On the basis of these properties, we next examined the acute effects of MK-8722 on glucose homeostasis in rodents. Remarkably, MK-8722 administration to lean, normoglycemic C57BL/6 mice reduced fasting blood glucose levels 1 hour after dose [immediately prior to the glucose challenge of an intraperitoneal glucose tolerance test (ipGTT)] (Fig. 2, A and B) . MK-8722 also improved glucose tolerance during the glucose challenge (Fig. 2, A and C) . Elevation of skeletal muscle pACC (14) established systemic AMPK activation by MK-8722 treatment (Fig. 2D) . The effects of MK-8722 were dose-dependent. Notably, improved glucose homeostasis using MK-8722 [30 mg/kg (mpk)] was achieved at significantly reduced plasma insulin levels during the ipGTT (Fig. 2E) . Similar improvements in glucose homeostasis were observed after acute MK-8722 treatment in every dysmetabolic and diabetic rodent model examined ( fig. S7 ), including the diabetic Goto-Kakizaki (GK) rat ( Fig. 2F  and fig. S8 ). Efficacious MK-8722 plasma concentrations were similar across all models, requiring minimal levels of~3 mM (~3 nM unbound).
To determine whether enhanced skeletal muscle glucose uptake underlies the acute glucoselowering effects of MK-8722, we quantitated the formation of nonmetabolizable 2-deoxy-D-glucose-6-phosphate (2DG6P), a product of cellular transport and intracellular phosphorylation, after exposure of cells or tissues to 2-deoxy-D-glucose (2DG) with or without MK-8722. Similar to insulin, MK-8722 treatment of primary human skeletal myocytes, in the absence of insulin, produced a dose-dependent increase in 2DG uptake by as much as a factor of 3 ( Fig. 3A) . Unlike insulin, MK-8722 treatment significantly increased intracellular pACC, reflective of AMPK activation (Fig.  3A) . Only the MK-8722 effects on 2DG uptake were suppressed by preincubation with the nonspecific AMPK inhibitor Compound C (Fig. 3C) . We also used a rat hindlimb in situ perfusion system in which 2DG and various concentrations of either insulin or MK-8722 were added to the perfusion buffer. MK-8722, in the absence of insulin, stimulated 2DG uptake and phosphorylation in a dosedependent manner, with an EC 50 of~2 to 4 mM (Fig. 3B ), identical to the minimal plasma levels required for glucose-lowering efficacy in vivo. Treatment with MK-8722 increased the amount of phosphorylated TBC1D1, an integral component of the Glut4 translocation pathway (4, 18) , in muscle cells ( fig. S5 ).
To confirm these effects in vivo, we challenged lean C57BL/6 mice with [ ) in an oGTT in diabetic GK rats (14-week-old male, n = 7 or 8 per group; data are representative of three independent experiments, unblinded). Data are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA.
in (5) and glycolysis (6) .
Chronic antihyperglycemic efficacy of MK-8722 was evaluated in db/db mice, a leptin receptordeficient T2DM model (19) . Once-daily administration of MK-8722 resulted in dose-dependent lowering of ambient blood glucose (Fig. 4A) . On treatment day 12, glucose reductions after MK-8722 treatment (30 mpk/day) were comparable to those observed with the PPARg agonist rosiglitazone (3 mpk/day) (Fig. 4A and fig. S10 ). Unlike rosiglitazone, the glucose-lowering action of MK-8722 manifested without significant effects on body weight ( fig. S10 ), which was a consistent finding. Dose-dependent increases in tissue pACC were maintained throughout the dosing period ( fig. S10 ). Chronic efficacy, without tachyphylaxis, was also observed in additional dysmetabolic and diabetic rodent models (figs. S11 and S12). In all cases, efficacy was associated with trough MK-8722 plasma levels comparable to the concentrations required to acutely stimulate skeletal muscle glucose uptake (Fig. 3) . Notably, chronic MK-8722 dosing in mice also increased muscle Glut4 protein levels, possibly contributing to efficacy ( fig. S13) (20) .
Efficacy was also assessed in a cohort of type 2 diabetic rhesus macaque nonhuman primates (T2DM NHPs) (21) . For these studies, we developed a less-invasive measure of AMPK activation that monitored pACC in peripheral blood mononuclear cells (PBMCs). The correlation between pACC formation in PBMCs versus muscle using both MSD and Western blot analysis is shown in fig. S14 . After administration of MK-8722 (5 mpk), pACC in PBMCs remained elevated for at least 10 hours (fig. S15) ; these effects were sustained during 7 weeks of dosing in T2DM NHPs ( fig. S16 ), demonstrating that AMPK activation by MK-8722 is not subject to tachyphylaxis.
The effect of both 5-and 10-mpk doses of MK-8722 in a mixed meal tolerance test (MMTT) was studied both acutely and after 7 weeks of continuous administration of MK-8722 [5 mpk/day orally (p.o.)]. A significant improvement in glucose excursion in the MMTT was observed only in the NHPs treated with MK-8722 (10 mpk) after both acute and chronic treatment (Fig. 4, B and  C, and fig. S17 ). A significant decrease in plasma insulin AUC (area under the curve) was observed at both doses and both time points (fig. S17 ).
HbA1c, a glycosylated form of hemoglobin, provides an integrated measure of blood glucose over~2 to 3 months in humans (22) . The relatively short duration of our T2DM NHP study suggested that HbA1c measurements might underestimate the "true" improvement in glucose control. Nonetheless, we observed an average 0.4% decrease in HbA1c in the 14 T2DM NHPs (Fig. 4D) . Ten NHPs exhibited a substantial 0.9% (±0.1% SEM) reduction in HbA1c. One NHP started the study with a nondiabetic HbA1c of 4.3%, which was not lowered further. Three severely diabetic NHPs did not respond to treatment; their HbA1c increased over the study period. 1,5-Anhydroglucitol and fructosamine, biomarkers of integrated glycemic control over shorter time frames [2 to 14 days and 2 to 3 weeks, respectively (22) ], responded appropriately to MK-8722 treatment (Fig. 4, E  and F ). There were no significant effects of MK-8722 treatment on food intake ( fig. S18 ). Blood chemistry was analyzed weekly. No reduction in fasted glucose levels before dosing (when MK-8722 concentrations were low) was observed ( fig.  S19 ). However, significant and comparable reductions in blood glucose were observed at both the beginning and end of the study 2 hours after dose using MK-8722 (10 mpk) ( fig. S19 ). Taken together, the results suggest that the observed antihyperglycemic effects were driven by acute, daily reductions in glucose that remained constant throughout the study. After the treatment period, the NHPs underwent a washout period. Although the time course for each NHP varied, all parameters returned to baseline, confirming that the changes were MK-8722-mediated and reversible (Fig. 4 , E and F, unshaded portion of the curves).
To confirm the mechanism of glucose lowering in NHP and examine a potentially useful clinical biomarker, we used [ We also investigated the potential cardiac safety concerns associated with chronic systemic AMPK activation. Cardiac safety was evaluated preclinically in Wistar Han rats and rhesus monkeys in studies lasting up to 8 months. Increased heart weight (normalized relative to brain weight, as compared with vehicle control) was observed in both male and female rats dosed with MK-8722 for 1 month at 10 and 30 mpk/day (Fig. 5A) . The increase in heart size was associated with increases in both cardiac and skeletal muscle C]D-glucose metabolite production in gastrocnemius muscle 2 hours after MK-8722 administration (10 mpk, p.o.) to GK rats (14-week-old male, n = 8 per group; data are representative of three independent experiments, unblinded). Data are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA.
glycogen ( fig. S21 ). Increased glycogen content was also evident upon histological assessment of cardiac samples from the study (fig. S22) . After a 2-month drug-free recovery period, both heart weight ( Fig.  5A) and muscle glycogen (fig. S21 ) returned to near control levels, demonstrating that the effects were both MK-8722-mediated and reversible.
The observed increases in cardiac glycogen after MK-8722 administration are much lower than those observed in the transgenic mouse models (23) and are dose-dependent, in contrast to heart weight increases (Fig. 5B) . Thus, the observed cardiac hypertrophy is not proportional to, nor solely a result of, glycogen accumulation. Cardiac hypertrophy in the absence of significant glycogen accumulation has been demonstrated in a human N488I PRKAG2 transgenic mouse model that coexpresses a mutant glycogen synthase incapable of Glc6P stimulation, but it is unclear whether the hypertrophy observed in this model is developmental in origin (23) .
Similarly, cardiac hypertrophy associated with increased cardiac and skeletal muscle glycogen was observed in rhesus monkeys dosed with MK-8722 for 1 month (Fig. 5C and fig. S23 ). Morphometric evaluation of the heart wall area confirmed an increase in one or both ventricles (table S3) . In rats, heart weight increases were greater after 6 months of dosing than after 1 month of dosing, demonstrating progression of the cardiac hypertrophy with increased duration of drug administration (table S4). ECG tracings obtained over an 8-month rhesus monkey study showed an increase in the amplitude of QRS at all doses, likely an effect secondary to the observed cardiac hypertrophy ( fig. S24 ). However, ECG changes similar to those associated with PRKAG2 mutation Wolff-ParkinsonWhite (WPW) syndrome (PR interval shortening, QRS prolongation) were not observed (9, 23, 24) . These results are consistent with data generated in transgenic PRKAG2 mouse models, which suggested that such conductance abnormalities (in particular, ventricular preexcitation) are due to structural defects created during cardiac development, possibly as a result of abnormal glycogen deposition secondary to AMPK disinhibition/activation caused by the PRKAG2 mutations (23, 24) . Normal cardiac function (ejection fraction and stroke volume) was demonstrated in rats that exhibited a 13% increase in heart weight after 1 month of MK-8722 administration ( fig. S25 ). Similar hypertrophic effects after chronic treatment were observed in all species and models examined, including both insulin-resistant mice dosed orally ( fig. S26 ) and diabetic db/db mice dosed in feed (Fig. 5D) .
Our results show that systemic, pharmacological pan-AMPK activation by MK-8722 leads to chronically sustainable improvements in glucose homeostasis, including the amelioration of insulin resistance and hyperglycemia (7, 8, 25) . No evidence of hypoglycemia was found in any study using MK-8722, including high-dose 6-to 8-month studies in normoglycemic rats and rhesus monkeys. These effects appear to be mediated predominantly by insulin-independent skeletal muscle glucose uptake. Glucose lowering without a requirement for increased insulin levels should (6-year-old male, n = 1; data are representative of three independent experiments, unblinded). Data are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, one-way ANOVA.
reduce the demand on the pancreatic b cell for insulin and, as a consequence, may increase the durability of antihyperglycemic action. This profile is both unique and highly desirable for patients with T2DM, differing from all currently available therapeutic agents (26, 27) .
On the other hand, MK-8722 treatment induced reversible cardiac hypertrophy that was not associated with notable functional sequelae or ECG abnormalities in the time frames studied. Our data suggest that this hypertrophy is not due to the observed cardiac glycogen accumulation. Rather, the effect is reminiscent of the physiological cardiac hypertrophy observed in elite athletes (28) . It is well established that exercise can activate cardiac AMPK (29) . Whether this effect is tolerable in humans having the pathophysiology of metabolic syndrome, obesity, and overt diabetes remains to be determined.
While this manuscript was in the final stages of review, Cokorinos et al. reported that a close analog of MK-8722 (PF-739) was able to activate skeletal muscle AMPK and lower glucose in preclinical species independent of hepatic AMPK activation (30) . (B) Effect on heart weight/brain weight ratio and cardiac glycogen after 2 weeks of MK-8722 administration (10 to 50 mpk/day, p.o.) in Wistar Han rats (6-week-old male, n = 5, single unblinded study). (C) Effect on heart weight/brain weight ratio of 1 month of MK-8722 administration (5 to 50 mpk/day, p.o.) in rhesus monkeys (sexes combined, n = 6 total; single unblinded study). (D) Effect on heart weight of 14-day MK-8722 administration (4 to 20 mpk/day in feed) in db/db mice (8-week-old male, n = 8; single unblinded study). Data are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, trend analysis (C), one-way ANOVA (other panels).
Glycogen
(mg/g heart) 10 
